Updated clinical classification of pulmonary hypertension

…, M Beghetti, RN Channick, M Delcroix… - Journal of the American …, 2009 - jacc.org
The aim of a clinical classification of pulmonary hypertension (PH) is to group together different
manifestations of disease sharing similarities in pathophysiologic mechanisms, clinical …

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary …

…, A Vonk Noordegraaf, M Delcroix… - European heart …, 2022 - academic.oup.com
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

Chronic thromboembolic pulmonary hypertension

NH Kim, M Delcroix, DP Jenkins, R Channick… - Journal of the American …, 2013 - jacc.org
Since the last World Symposium on Pulmonary Hypertension in 2008, we have witnessed
numerous and exciting developments in chronic thromboembolic pulmonary hypertension (…

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European …

…, R Benza, R Berger, D Bonnet, M Delcroix… - European heart …, 2009 - academic.oup.com
Thus, the task of writing Guidelines or Expert Consensus documents covers not only the
integration of the most recent research, but also the creation of educational tools and …

[HTML][HTML] Inhaled iloprost for severe pulmonary hypertension

…, M Delcroix, M Gomez-Sanchez… - … England Journal of …, 2002 - Mass Medical Soc
Background Uncontrolled studies suggested that aerosolized iloprost, a stable analogue of
prostacyclin, causes selective pulmonary vasodilatation and improves hemodynamics and …

[HTML][HTML] Macitentan and morbidity and mortality in pulmonary arterial hypertension

…, I Adzerikho, RN Channick, M Delcroix… - … England Journal of …, 2013 - Mass Medical Soc
Background Current therapies for pulmonary arterial hypertension have been adopted on the
basis of short-term trials with exercise capacity as the primary end point. We assessed the …

Chronic thromboembolic pulmonary hypertension (CTEPH) results from an international prospective registry

J Pepke-Zaba, M Delcroix, I Lang, E Mayer, P Jansa… - Circulation, 2011 - Am Heart Assoc
Background— Chronic thromboembolic pulmonary hypertension (CTEPH) is often a sequel
of venous thromboembolism with fatal natural history; however, many cases can be cured by …

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

…, A Torbicki, M Delcroix, R Naeije, M Hoeper… - Journal of the American …, 2002 - jacc.org
… group from 362 ± 94 m to 377 ± 106 m at week 6 and to 377 ± 113 m at week 12. The …
group from 383 ± 93 m to 388 ± 111 m at week 6 and decreased to 374 ± 121 m at week 12. The …

Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic …

…, AM D'Armini, P Jansa, A Torbicki, M Delcroix… - Journal of the American …, 2008 - jacc.org
Objectives : Our goal was to investigate the effect of treatment with the oral dual endothelin
receptor antagonist bosentan on the hemodynamics and exercise capacity of patients with …

ERS statement on chronic thromboembolic pulmonary hypertension

M Delcroix, A Torbicki, D Gopalan… - European …, 2021 - Eur Respiratory Soc
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute
pulmonary embolism, either symptomatic or not. The occlusion of proximal pulmonary arteries …